{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/neuropathic-pain-drug-treatment/prescribing-information/gabapentin/","result":{"pageContext":{"chapter":{"id":"498f1249-e619-5b41-b42b-1a914239d269","slug":"gabapentin","fullItemName":"Gabapentin","depth":2,"htmlHeader":"<!-- begin field 17122abd-3fbf-4b4e-951d-18576a7599ba --><h2>Gabapentin</h2><!-- end field 17122abd-3fbf-4b4e-951d-18576a7599ba -->","summary":"","htmlStringContent":"<!-- begin item 32b22b65-ae32-4087-b951-39a41d2fd915 --><!-- end item 32b22b65-ae32-4087-b951-39a41d2fd915 -->","topic":{"id":"b1f9c908-6cb6-5afd-a737-0a621c6232d0","topicId":"35e3d915-8243-4418-a7dd-6590d8ca5c85","topicName":"Neuropathic pain - drug treatment","slug":"neuropathic-pain-drug-treatment","lastRevised":"Last revised in December 2020","chapters":[{"id":"0c243e96-3697-5ee3-98c7-9ffecf07f2af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94d784c6-0537-5187-a548-a95e6ad2f899","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"855f03f8-54cb-5675-a6b8-aeb8064288d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f0b9b63a-bd52-51b6-8eda-cb26c9f551a0","slug":"changes","fullItemName":"Changes"},{"id":"2e3e3fff-20af-56ab-b8f8-a9ee4f14f833","slug":"update","fullItemName":"Update"}]},{"id":"80218328-d006-5b34-a01a-0ef4dbeaf7d5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"22989c5e-df85-5aba-bd66-8c44723e59d7","slug":"goals","fullItemName":"Goals"},{"id":"722de221-9258-5985-8a02-c088cf258a12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bf3b0c22-2d82-5464-bf76-bc066dae256f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c6576f2f-fd04-5900-a5e1-517233523e2c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd2de31a-79d5-5c20-9132-c99c41c12822","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"148cc621-37d8-5264-a358-c380fcfb4223","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"eddf36b3-7bc8-53c9-9c59-fa36b809f229","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025ef443-81b5-565d-8240-d76615c27e55","slug":"definition","fullItemName":"Definition"},{"id":"3704349e-d3ae-5a8b-ba94-9da5282ed77f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e18339e8-95d0-582f-ad51-0614dae8f855","slug":"complications","fullItemName":"Complications"},{"id":"9b552f08-01aa-583d-900b-9cbdc90fe28d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"21d7485a-b855-5ba4-82bc-ca3154184325","fullItemName":"Management","slug":"management","subChapters":[{"id":"bad22859-57ae-5c1c-a944-c3d9fef6d160","slug":"neuropathic-pain-drug-treatment","fullItemName":"Scenario: Neuropathic pain - drug treatment"}]},{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a91a8f28-db46-58e8-9df7-f30be0f00f2b","slug":"amitriptyline","fullItemName":"Amitriptyline"},{"id":"382b9603-7b46-57d1-9b07-fa743886796e","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"498f1249-e619-5b41-b42b-1a914239d269","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"201a6fcc-11c6-5f00-b820-7fa69ee8b95d","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"56e4231d-ab93-5963-bc8a-989240189179","slug":"capsaicin-cream","fullItemName":"Capsaicin cream"},{"id":"01a263c7-9fe1-5a29-95ec-24e56c0c1bc9","slug":"tramadol","fullItemName":"Tramadol"}]},{"id":"9ed9a9fb-0b52-50ef-8980-c1303531094d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4fd6ab13-09e0-57f4-a265-464eeab8c835","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3eb7f136-ffd0-5f27-b2d1-21b49247596d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"606fc7bf-da44-5385-95f8-0139b3c57ef7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9fc3997f-80c3-5333-b5bd-3b3a518bdde6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"74708745-26ce-5fd4-8c02-67ba25b5a355","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f5855b4-c905-54ca-b02a-820f8fdd4a4a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f09723db-fe39-5bbd-b643-d063fcd61d42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"757d5eff-92be-5420-a880-d4bf8f8feb26","slug":"licensed-indications","fullItemName":"Licensed indications","depth":3,"htmlHeader":"<!-- begin field 91af0c3c-0e61-4c8f-b477-17ace374a2fd --><h3>Is gabapentin licensed for neuropathic pain?</h3><!-- end field 91af0c3c-0e61-4c8f-b477-17ace374a2fd -->","summary":"","htmlStringContent":"<!-- begin item 0a728ad5-797d-43ce-bb9a-282c658dfc6c --><!-- begin field cace88d5-0a75-4783-8a5d-e893bba708d9 --><ul><li>Gabapentin is licensed for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and postherpetic neuralgia in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020a</a>]. </li><li>However, the National Institute for Health and Care Excellence (NICE) recommends gabapentin as a first-line treatment option for adults with all neuropathic pain (except trigeminal neuralgia) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">NICE, 2019a</a>]. </li></ul><!-- end field cace88d5-0a75-4783-8a5d-e893bba708d9 --><!-- end item 0a728ad5-797d-43ce-bb9a-282c658dfc6c -->","subChapters":[]},{"id":"e5810285-a375-54da-9e0a-db5ec1c21b95","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 2c0bba8f-2c4d-43d4-b3b0-25055de030c0 --><h3>Dose and titration</h3><!-- end field 2c0bba8f-2c4d-43d4-b3b0-25055de030c0 -->","summary":"","htmlStringContent":"<!-- begin item dd0efb19-8472-481e-afc5-7a47e5e7144e --><!-- begin field 1cfd1d2e-19a8-4aa1-9257-0f7e1aa39394 --><ul><li><strong>Fast titration </strong>(usually suitable for otherwise healthy younger adults).<ul><li>Initially, 300 mg once a day on day 1, then 300 mg twice a day on day 2, then 300 mg three times a day on day 3.</li><li>Alternatively, start with 300 mg three times a day on day 1, then increase according to response in steps of 300 mg (in three divided doses) every 2–3 days up to maximum of 3600 mg a day (1200 mg three times a day).<ul><li>If the person experiences adverse effects during daily titration, a slower titration may help.</li></ul></li></ul></li><li><strong>Slow titration </strong>(suitable if the person is elderly, frail, or has experienced adverse effects with higher doses).<ul><li>Start with 100 mg at night, increasing by 100 mg a day until pain is significantly reduced, intolerable adverse effects occur, or a maximum daily dosage of 3600 mg (1200 mg three times a day) is reached [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Dworkin, 2007&nbsp;</a>].<ul><li>If the person experiences adverse effects during daily titration, a slower titration (for example increasing the dose every 3–7 days) may help.</li></ul></li></ul></li><li>Consider trialling gabapentin for 3–8 weeks, with at least 2 weeks at the maximum tolerated dose, before deciding it is not effective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Dworkin, 2007&nbsp;</a>].<ul><li>It may take several weeks to reach an effective dosage (usually 1200 mg to 3600 mg a day). Onset of action may be seen as early as the second week of treatment with rapid titration, but the peak effect usually occurs about 2 weeks after a therapeutic dosage is achieved; therefore, an adequate trial may be 2 months or longer.</li></ul></li><li>If gabapentin is not effective or not tolerated, discontinue treatment gradually over a minimum of 1 week.</li><li>Adjust the dose for people with renal impairment (see Table 2). Consult the manufacturer's Summary of Product Characteristics if the person is undergoing haemodialysis.</li></ul><p><strong>Table 2.</strong> Recommended dosage adjustment for gabapentin in people with renal impairment.</p><table><thead><tr><th colspan=\"1\">Renal function (based on eGFR)</th><th colspan=\"1\">Starting daily dose (to be administered as three divided doses)</th><th colspan=\"1\">Maximum daily dosage (to be administered as three divided doses)</th></tr></thead><tbody><tr><td colspan=\"1\">eGFR 50–79 mL per minute per 1.73 m<sup>2</sup></td><td colspan=\"1\">600 mg</td><td colspan=\"1\">1800 mg a day</td></tr><tr><td colspan=\"1\">eGFR 30–49 mL per minute per 1.73 m<sup>2</sup></td><td colspan=\"1\">300 mg</td><td colspan=\"1\">900 mg a day</td></tr><tr><td colspan=\"1\">eGFR 15–29 mL per minute per 1.73 m<sup>2 </sup>(stage 4, severe)</td><td colspan=\"1\">300 mg on alternate days</td><td colspan=\"1\">600 mg a day</td></tr><tr><td colspan=\"1\">eGFR less than 15 mL per minute per 1.73 m<sup>2 </sup>(stage 5, very severe or endstage)</td><td colspan=\"1\">300 mg on alternate days</td><td colspan=\"1\">300 mg a day</td></tr><tr><td colspan=\"3\">eGFR = estimated glomerular filtration rate</td></tr><tr><td colspan=\"3\">Data from [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>]</td></tr></tbody></table><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 1cfd1d2e-19a8-4aa1-9257-0f7e1aa39394 --><!-- end item dd0efb19-8472-481e-afc5-7a47e5e7144e -->","subChapters":[]},{"id":"7129e8bf-fc47-5c41-be96-44d8e7cc1644","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field de7dc366-6a33-4676-b0f0-ab9db95c699a --><h3>Contraindications and cautions</h3><!-- end field de7dc366-6a33-4676-b0f0-ab9db95c699a -->","summary":"","htmlStringContent":"<!-- begin item b6fc8cbe-aed7-4823-9ede-daaa52e82969 --><!-- begin field b0032326-54eb-413e-ba50-099f6718f8f6 --><ul><li><strong>Prescribe gabapentin with caution to people with:</strong><ul><li>A history of substance abuse.</li><li>A history of psychotic illness. </li><li>Low body weight (high doses of oral solution).</li><li>Mixed seizures (including absences). </li><li>Diabetes mellitus. </li><li>Renal impairment – dose adjustments are necessary.</li></ul></li><li><strong>Also prescribe gabapentin with caution to people who are:</strong><ul><li>Elderly.  </li><li>At risk of suicide.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>] </p><!-- end field b0032326-54eb-413e-ba50-099f6718f8f6 --><!-- end item b6fc8cbe-aed7-4823-9ede-daaa52e82969 -->","subChapters":[]},{"id":"c85d240a-eb48-5eb7-817b-e78cb4bf47ec","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field fcfd176c-e70e-4688-b8a8-3909709f4688 --><h3>Adverse effects </h3><!-- end field fcfd176c-e70e-4688-b8a8-3909709f4688 -->","summary":"","htmlStringContent":"<!-- begin item 45e35c6a-e0e7-4857-bbcd-33010e7e58de --><!-- begin field 6ce5af48-1096-4684-8f07-0d759fd90635 --><ul><li><strong>Gastrointestinal</strong> — vomiting, nausea, constipation, diarrhoea, flatulence, abdominal pain, dry mouth, gingivitis (common); pancreatitis (frequency unknown).</li><li><strong>Infections and infestations</strong> — viral infection (very common); pneumonia, respiratory infection, urinary tract infection, otitis media (common).</li><li><strong>Metabolism and nutrition</strong> — anorexia, increased appetite (common); hyperglycaemia (uncommon); hyponatraemia (frequency unknown).</li><li><strong>Musculoskeletal and connective tissue</strong> — arthralgia, myalgia, back pain, twitching (common); rhabdomyolysis, myoclonus (frequency unknown).</li><li><strong>Nervous system</strong> — dizziness, somnolence, ataxia (very common); headache, convulsions, hyperkinesia, tremor, dysarthria, amnesia, insomnia, paraesthesia, nystagmus (common); hypokinesia, mental impairment (uncommon).<ul><li><strong>Rarely:</strong> loss of consciousness.</li></ul></li><li><strong>Psychiatric</strong> — hostility, confusion and emotional lability, depression, anxiety, nervousness (common); agitation (uncommon); hallucinations (unknown frequency).<ul><li><strong>Suicidal thoughts and behaviour.</strong> There is a small increased risk of suicidal thoughts and behaviour associated with antiepileptic drugs (including gabapentin), which may be seen as early as 1 week after starting treatment.<ul><li>Advise people taking gabapentin to be alert to any mood changes, distressing thoughts, or feelings about suicide or harming themselves at any point during treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">MHRA, 2008</a>].</li><li>They should seek medical advice if they develop such thoughts or behaviour, and they should be referred for appropriate treatment if necessary.</li></ul></li></ul></li><li><strong>Skin and subcutaneous tissue</strong> — facial oedema, purpura, rash, pruritus, acne (common); Stevens-Johnson syndrome, angioedema, alopecia, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme (frequency unknown).</li><li><strong>Other adverse effects include: </strong><ul><li>Acute renal failure, incontinence.</li><li>Allergic reactions. </li><li>Dyspnoea, respiratory depression.</li><li>Fatigue, fever.</li><li>Impotence. </li><li>Hepatitis, jaundice. </li><li>Hypertension, vasodilation.</li><li>Leucopenia, thrombocytopenia. </li><li>Peripheral oedema.</li><li>Palpitations.</li><li>Vertigo.</li><li>Visual disturbances. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Joint Formulary Committee, 2020</a>] ​​​​​​​</p><!-- end field 6ce5af48-1096-4684-8f07-0d759fd90635 --><!-- end item 45e35c6a-e0e7-4857-bbcd-33010e7e58de -->","subChapters":[]},{"id":"b64dfd99-1a54-5d15-9d18-babbb3caa338","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1089872e-019e-44ab-8079-1bec3c516c14 --><h3>Drug interactions </h3><!-- end field 1089872e-019e-44ab-8079-1bec3c516c14 -->","summary":"","htmlStringContent":"<!-- begin item 9ed339f4-1006-42b9-b573-1115fce5638b --><!-- begin field ed3bb99f-4279-4909-a28c-2a9b36482450 --><ul><li><strong>Antacids</strong> — levels of gabapentin are reduced slightly if taken concurrently with antacids containing aluminium/magnesium hydroxide. Gabapentin should be taken 2 hours after the antacid.</li><li><strong>Orlistat </strong>— the levels of gabapentin may be reduced. </li><li><strong>Opioids</strong> (tramadol, fentanyl) — the analgesic effect of opioids may be enhanced if taken concurrently with gabapentin. Monitor for signs of central nervous system (CNS) depression (such as somnolence) and adjust the dose of gabapentin, or the opioid if required.</li><li><strong>Sevelamer</strong> — absorption of gabapentin may be reduced if taken concurrently with sevelamer. Gabapentin should be taken at least 1 hour before, or 3 hours after, sevelamer if the reduction in gabapentin levels is clinically significant.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">Preston, 2016</a>]</p><!-- end field ed3bb99f-4279-4909-a28c-2a9b36482450 --><!-- end item 9ed339f4-1006-42b9-b573-1115fce5638b -->","subChapters":[]},{"id":"fe7e0519-5a3f-5fc4-9168-e3cc35cff665","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field efc12a19-e2e2-4512-a499-7777b261ecf1 --><h3>Pregnancy and breastfeeding</h3><!-- end field efc12a19-e2e2-4512-a499-7777b261ecf1 -->","summary":"","htmlStringContent":"<!-- begin item 203f44a6-b067-485b-afe1-f03aaa7c7f41 --><!-- begin field 868e08ad-9ea8-4ec6-8b15-918bea9ad352 --><h4>Pregnancy</h4><ul><li>There are limited data on the use of gabapentin in women who are pregnant.</li><li>Gabapentin should be avoided in pregnancy unless the benefit to the mother outweighs the risk to the fetus.</li></ul><h4>Breastfeeding</h4><ul><li>Limited data indicate that gabapentin is excreted in low amounts in breastmilk.<ul><li>Maternal doses of gabapentin up to 2.1 grams daily produce relatively low levels in infant serum. The US Drugs and Lactation Database (LactMed) advises monitoring the infant for drowsiness, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of anticonvulsant or psychotropic drug.</li></ul></li><li>The manufacturer advises gabapentin should only be used in women who are breastfeeding if the benefits outweigh the potential risks.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">LactMed, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">UKTIS, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/neuropathic-pain-drug-treatment/references/\">ABPI, 2020a</a>]</p><!-- end field 868e08ad-9ea8-4ec6-8b15-918bea9ad352 --><!-- end item 203f44a6-b067-485b-afe1-f03aaa7c7f41 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}